Glucagon: Recent Developments in Managing Severe Hypoglycemia

Glucagon: Recent Developments in Managing Severe Hypoglycemia

On-Demand 0.75-hour Accredited Webcast originally presented at the 11th Annual Directions in Pharmacy® Spring Conference on June 5, 2021.

Faculty Presenter

Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM
Associate Professor/Associate Director of Skills Education, Clinical Pharmacist
Rosalind Franklin University of Medicine and Science College of Pharmacy
North Chicago, Illinois

Lake County Health Department
Waukegan, Illinois

Moderator

Jessica L. Kerr, PharmD, CDCES
Associate Dean, Office of Professional and Student Affairs
Professor, Department of Pharmacy Practice
Southern Illinois University Edwardsville School of Pharmacy
Edwardsville, Illinois
 
Program Description
There are 34.2 million Americans living with diabetes with 6.8 million taking insulin. While the concern of hyperglycemia is well known, there is a need for increased awareness on the burden of  hypoglycemia in these patients. If left untreated, hypoglycemia can lead to severe symptoms including coma and death. A patient’s fear of hypoglycemia can lead to negative coping strategies, which may become a barrier to achieving glycemic goals or lead to an unwillingness to intensify therapy. Prevention of hypoglycemia is key, and pharmacists play an important role in identifying patients who are at risk of hypoglycemia and educating patients about the critical role of glucagon products. In recent years, there have been various glucagon products approved that offer patients different options including unique routes of administration and dosing or generic options. Pharmacists should understand the differences in available dosage forms, dosing, indications, administration, safety, and storage to ensure they educate patients about the safe and appropriate use of the various glucagon products.  

Target audience: Community pharmacists
Type of activity: Knowledge
Release date: June 15, 2021
Expiration date: June 15, 2022
Time to complete activity: 0.75 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Discuss hypoglycemia including risk factors, signs and symptoms, and its burden on persons with diabetes
• Review glucagon products used for the management of severe hypoglycemia and the safety and efficacy of these options 
• Recognize the role of the pharmacist in educating persons with diabetes and caregivers on the safe and appropriate use of glucagon products

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-21-247-H01-P. The activity is available for CE credit through June 15, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty
 
Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM, has no financial relationships with commercial interests to disclose.

Moderator

Jessica L. Kerr, PharmD, CDCES, has no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms